Rapid defervescence after doxycycline treatment of macrolide-resistant Mycoplasma pneumoniae-associated community-acquired pneumonia in children

Pediatr Infect Dis J. 2013 Dec;32(12):1396-9. doi: 10.1097/INF.0b013e3182a25c71.

Abstract

We did a retrospective review of children with Mycoplasma pneumoniae infection hospitalized from March 2010 to March 2013. Mycoplasma-resistant M. pneumoniae constituted 70% of the total M. pneumoniae-associated community-acquired pneumonia. Doxycycline was significantly more effective than macrolide for treatment of Mycoplasma-resistant M. pneumoniae-associated community-acquired pneumonia in terms of achievement of rapid defervescence within 24 hours.

MeSH terms

  • Adolescent
  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use*
  • Child
  • Child, Preschool
  • Community-Acquired Infections / drug therapy*
  • Community-Acquired Infections / epidemiology
  • Community-Acquired Infections / microbiology*
  • Doxycycline / therapeutic use*
  • Drug Resistance, Bacterial
  • Female
  • Fever / microbiology
  • Hong Kong / epidemiology
  • Humans
  • Macrolides / pharmacology
  • Macrolides / therapeutic use*
  • Male
  • Mycoplasma pneumoniae / drug effects
  • Pneumonia, Mycoplasma / drug therapy*
  • Pneumonia, Mycoplasma / epidemiology
  • Pneumonia, Mycoplasma / microbiology*
  • Retrospective Studies

Substances

  • Anti-Bacterial Agents
  • Macrolides
  • Doxycycline